Goldman Sachs
NPCE icon

Goldman Sachs’s Neuropace NPCE Stock Holding History

Goldman Sachs’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.31M Buy
175,362
+10,652
+6% +$160K ﹤0.01% 4413
2025
Q4 		$2.54M Sell
164,710
-21,828
-12% -$292K ﹤0.01% 4360
2025
Q3 		$1.92M Buy
186,538
+127,885
+218% +$1.21M ﹤0.01% 4519
2025
Q2 		$653K Buy
58,653
+24,427
+71% +$305K ﹤0.01% 4996
2025
Q1 		$421K Sell
34,226
-8,057
-19% -$101K ﹤0.01% 5287
2024
Q4 		$473K Buy
42,283
+19,857
+89% +$173K ﹤0.01% 5278
2024
Q3 		$156K Sell
22,426
-1,522
-6% -$11.1K ﹤0.01% 5511
2024
Q2 		$181K Sell
23,948
-115,895
-83% -$1.17M ﹤0.01% 5293
2024
Q1 		$1.85M Buy
+139,843
New +$1.99M ﹤0.01% 3926

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs's NPCE Position: Q1 2026 in Review

Goldman Sachs increased its Neuropace (NPCE) stake by 6.5% in Q1 2026, buying an estimated $160K and bringing the position to 175,362 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4413.

Goldman Sachs first reported a position in NPCE in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.54M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Goldman Sachs held 175,362 shares of Neuropace worth $2.31M as of Q1 2026.
  • Goldman Sachs bought 10,652 Neuropace shares in Q1 2026, an estimated $160K.
  • Neuropace made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4413 holding.
  • Goldman Sachs first reported a position in Neuropace in Q1 2024 and has held it in 9 quarters since.
  • Goldman Sachs's Neuropace position peaked at $2.54M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.